A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes
| Image |  |
|---|---|
| Description | scientific article published on 04 November 2020 |
| Author/s |
author: Joao Oliveira Chantal Mathieu Robert Hilbrands Bart Roep Frans Gorus Nicolas Wisniacki Dave Inman Pieter Gillard |
| Publication date | November 4, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |